Tigecycline is owned by Amneal.
Tigecycline contains Tigecycline.
Tigecycline has a total of 1 drug patent out of which 0 drug patents have expired.
Tigecycline was authorised for market use on 02 August, 2018.
Tigecycline is available in powder;intravenous dosage forms.
The generics of Tigecycline are possible to be released after 07 April, 2033.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9855335 | AMNEAL | Tigecycline composition for injection |
Apr, 2033
(10 years from now) |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 02 August, 2018
Treatment: NA
Dosage: POWDER;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic